Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03806283 · ClinicalTrials.gov registry record
Mechanisms of Pregnancy Vascular Adaptations
A clinical trial of Preeclampsia and Vascular Diseases, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 166
- Enrollment target
- 1
- Study location
NCT03806283: Recruiting study of Preeclampsia and Vascular Diseases, sponsored by University of Wisconsin, Madison.
NCT03806283 is a study of Preeclampsia and Vascular Diseases that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 166 participants, below the 1,123-participant average among 48 other Preeclampsia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03806283, a study of Preeclampsia and Vascular Diseases, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will collect omental tissue (research surgical excision) and placental tissue (standard of care clinical delivery) from both preeclamptic and non-preeclamptic women during their c-section and use these samples to study the blood vessels, specifically the expression/activation of the AT2R.
Primary Outcome
The researchers will measure the amount and distribution of vascular angiotensin II type 1 receptor (AT1R) and AT2R during normal human pregnancy and in preeclampsia. The researchers will assess if AT2R expression varies with severity of preeclampsia. Based on pilot data, the researchers expect decreased AT2R and increased AT1R protein levels in preeclamptic vs normotensive vessels.
Conditions Studied
Interventions
- PROCEDURE Omental Biopsy
Study Locations (1)
Wisconsin
- UnityPoint Health-Meriter Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2027-04 |
What NCT03806283 shows while recruiting
NCT03806283 is an observational study that tracks outcomes without assigning an intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 1,123-participant average among 48 other Preeclampsia trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Omental Biopsy is the first listed.
NCT03806283 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03806283 about?
NCT03806283 is a clinical study titled "Mechanisms of Pregnancy Vascular Adaptations". The investigators will collect omental tissue (research surgical excision) and placental tissue (standard of care clinical delivery) from both preeclamptic and non-preeclamptic women during their c-section and use these samples to study the blood vessels, specifically the expression/activation of th...
What is the current status of trial NCT03806283?
This trial is currently recruiting. The enrollment target is 166 participants. The study started on 2018-11-20. Estimated completion is 2027-04.
What conditions does trial NCT03806283 study?
This clinical trial studies the following conditions: Preeclampsia, Vascular Diseases.
What interventions are being tested in trial NCT03806283?
The interventions under investigation include: Omental Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03806283?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03806283 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03806283's enrollment target sits among peer trials
166 22nd of 48 higher than 27 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
- NCT04501406 · 166 participants · Phase 2
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI